U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT06992687) titled 'A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors' on April 23.
Brief Summary: To evaluate the safety and tolerability of HB0052 in patients with advanced solid tumors
Study Start Date: Sept. 01, 2024
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
DRUG: HB0052 Injection
An antibody- drug conjugate (ADC) that targets CD73 with SN38 as the payload
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
Disclaimer: Curated by HT Syndication....